在炎症性肠道疾病中以模型为基础的精确剂量
Arno R Bourgonje1, Marla C Dubinsky2, Ron J Keizer3
1The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Trends in pharmacological sciences
|December 4, 2024
概括
对于炎症性肠病 (IBD) 的治疗药物监测 (TDM) 需要改进. 新的工具,如基于模型的精确剂量 (MIPD) 提供个性化治疗策略,以改善患者的治疗结果.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 治疗药物监测 (TDM) 对于优化炎症性肠病 (IBD) 的生物疗法至关重要.
- 目前的TDM方法面临挑战,包括确定最佳药物度,管理药理动力学 (PK) 和药理动力学 (PD) 变化,以及临床决策的延迟.
- 一种适合所有人的TDM方法不足以满足IBD患者的各种需求.
研究的目的:
- 探索最近的技术进步,解决IBD的TDM未得到满足的需求.
- 评估基于模型的精确剂量 (MIPD) 对IBD个性化生物治疗的潜力.
- 要突出创新如何可以推进TDM超越当前的局限性.
主要方法:
- 对IBD的TDM近期技术进步的审查.
- 讨论人口PK/PD建模和MIPD工具.
- 考虑 Point-of-Care (POC) 和自取样测试,以及新的软件解决方案.
主要成果:
- 人口PK/PD建模和MIPD工具提供了优化IBD生物剂量的解决方案.
- POC和自取样分析,以及新的软件,可以简化TDM流程.
- 这些创新有可能克服当前的TDM挑战.
结论:
- 成功实施MIPD可以为IBD患者建立个性化的剂量策略.
- 与传统的,不充分的TDM方法相比,MIPD是一个显著的进步.
- 通过MIPD个性化剂量是满足所有IBD患者复杂需求的关键.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115